FILE PHOTO: People pose with syringe with needle in front of displayed AstraZeneca logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration
December 23, 2021
(Reuters) – A three-dose course of AstraZeneca’s COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19.
After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus’s Delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
Source: One America News Network
